HLHui Li

Hui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Li has a total of 272 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Hu

    Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao‐Yang Hospital Capital Medical University Beijing China

    35 shared publications
  • Xin Li

    Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

    17 shared publications
  • Ming-Ming Shao

    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

    16 shared publications
  • Qing-Yu Chen

    Department of Respiratory and Critical Care Medicine Beijing Institute of Respiratory Medicine and Beijing Chao‐Yang Hospital, Capital Medical University Beijing China

    15 shared publications
  • Rui-Qi Wei

    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 1

    15 shared publications
  • Xin Qiao

    Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. 1

    15 shared publications

Latest Publications

  • Open Access

    Supplementary Fig.4 from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    Bioluminescence imaging of MSL3P1 knockdown or overexpression on the localization of LUAD cells in the lungs of nude mice.

  • Open Access

    Supplementary Fig. 1 from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    MSL3P1 is upregulated in a variety of cancers.

  • Open Access

    Supplementary Fig. 3 from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    MSL3P1 regulates the invasion through CUL3 in LUAD.

  • Open Access

    Data from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    Lung adenocarcinoma (LUAD) is the most prevalent histological type of lung cancer. Previous studies have reported that specific long noncoding RNAs (lncRNA) are involved in cancer development and progression. The phenotype and mechanism of ENST00000440028, named MSL3P1, an lncRNA referred to as a cancer-testis gene with potential roles in tumorigenesis and progression, have not been reported. MSL3P1 is overexpressed in LUAD tumor tissues, which is significantly associated with clinical characteristics, metastasis, and poor clinical prognosis. MSL3P1 promotes the metastasis of LUAD in vitro and in vivo. The enhancer reprogramming in LUAD tumor tissue is the major driver of the aberrant expression of MSL3P1. Mechanistically, owing to the competitive binding to CUL3 mRNA with ZFC3H1 protein (a protein involved in targeting polyadenylated RNA to exosomes and promoting the degradation of target mRNA), MSL3P1 can prevent the ZFC3H1-mediated RNA degradation of CUL3 mRNA and transport it to the cytoplasm. This activates the downstream epithelial-to-mesenchymal transition signaling pathway and promotes tumor invasion and metastasis.Implications:This study indicates that lncRNA MSL3P1 regulates CUL3 mRNA stability and promotes metastasis and holds potential as a prognostic biomarker and therapeutic target in LUAD.


  • Open Access

    Association Between Neutrophil Percentage-to-Albumin Ratio (NPAR) and the Prognosis of Non-Small-Cell Lung Cancer

    by Xin Ye, Yi Liu, Fanjie Meng, Bin Hu, Hui Li

    Objective: This study investigates the prognostic value and clinical utility of the neutrophil percentage-to-albumin ratio (NPAR) in patients with resected non-small-cell lung cancer (NSCLC). Methods: We retrospectively included 335 patients with NSCLC who underwent lung resection at our institution between January 2017 and October 2018. Optimal cutoffs for preoperative and postoperative day 1 (D1) NPAR were determined using X-tile (version 3.6.1; Yale University, New Haven, CT, USA) to define high and low groups. Overall survival (OS) was evaluated using Kaplan–Meier analysis and Cox proportional hazards models. A perioperative NPAR trajectory (low–low, low–high, high–low, high–high) was constructed to characterize dynamic risk patterns. To mitigate potential bias associated with postoperative measurements, a D1 landmark analysis was performed. A nomogram was developed based on the multivariable model and assessed by calibration at 1, 3, and 5 years. Incremental clinical value beyond TNM stage and surgical approach was evaluated using decision curve analysis (DCA), as well as by 5-year continuous net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: The optimal cutoffs for preoperative and postoperative D1 NPAR were 14.5 and 23.1, respectively. In univariate analyses, sex, smoking history, preoperative NPAR, postoperative D1 NPAR, pathologic type, TNM stage, surgical approach, and adjuvant therapy were associated with OS (all p < 0.01). In multivariable Cox regression, high preoperative NPAR (HR 1.896, 95% CI 1.135–3.168; p = 0.014) and high postoperative D1 NPAR (HR 1.905, 95% CI 1.097–3.305; p = 0.014) were independent risk factors, along with TNM stage (Stage II: HR 2.824, 95% CI 1.209–6.595; p = 0.016; Stage III: HR 9.470, 95% CI 4.935–18.171; p < 0.001) and open surgery (HR 2.350, 95% CI 1.341–4.117; p = 0.003). Trajectory analysis further stratified risk, with the high–high group showing the poorest survival (adjusted HR 3.48, 95% CI 1.43–8.47; p = 0.006). The association of postoperative NPAR persisted in the D1 landmark analysis (HR 1.836, 95% CI 1.071–3.148; p = 0.027). Adding NPAR to TNM stage and surgical approach improved 5-year risk reclassification (continuous NRI 0.377, 95% CI 0.094–0.659; IDI 0.028, 95% CI −0.002–0.054) and increased net benefit on DCA. The nomogram demonstrated acceptable calibration at 1, 3, and 5 years. Conclusions: This study demonstrates that NPAR serves as an independent prognostic marker for long-term outcomes in patients with NSCLC. The use of NPAR offers clinicians a comprehensive and precise tool for assessing patient prognosis.

  • Open Access

    Identification of Major Bleeding Events in Postoperative Patients With Malignant Tumors in Chinese Electronic Medical Records: Algorithm Development and Validation

    by Hui Li, Haiyang Yao, Yuxiang Gao, Hang Luo, Changbin Cai, Zhou Zhou, Muhan Yuan, Wei Jiang

    Background: Postoperative bleeding is a serious complication following abdominal tumor surgery, but it is often not clearly diagnosed and documented in clinical practice in China. Previous studies have relied on manual interpretation of medical records to determine the presence of postoperative bleeding in patients, which is time-consuming and laborious. More critically, this manual approach severely hinders the efficient analysis of large volumes of medical data, impeding in-depth research into the incidence patterns and risk factors of postoperative bleeding. It remains unclear whether machine learning can play a role in processing large volumes of medical text to identify postoperative bleeding effectively. Objective: This study aimed to develop a machine learning model tool for identifying postoperative patients with major bleeding based on the electronic medical record system. Methods: This study used data from the available information in the National Health and Medical Big Data (Eastern) Center in Jiangsu Province of China. We randomly selected the medical records of 2,000 patients who underwent in-hospital tumor resection surgery between January 2018 and December 2021 from the database. Physicians manually classified each note as present or absent for a major bleeding event during the postoperative hospital stay. Feature engineering involved bleeding expressions, high-frequency related expressions, and quantitative logical judgment, resulting in 270 features. Logistic regression (LR), K-nearest neighbor (KNN), and convolutional neural network (CNN) models were developed and trained using the 1600-note training set. The main outcomes were accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for each model. Results: Major bleeding was present in 4.31% (69/1600) of the training set and 4.75% (19/400) of the test set. In the test set, the LR method achieved an accuracy of 0.8275, a sensitivity of 0.8947, a specificity of 0.8241, a PPV of 0.2024, an NPV of 0.9937, and an F1-score of 0.3301. The CNN method demonstrated an accuracy of 0.8900, sensitivity of 0.8421, specificity of 0.8924, PPV of 0.2807, NPV of 0.9913, and an F1-score of 0.4211. While the KNN method showed a high specificity of 0.9948 and an accuracy of 0.9575 in the test set, its sensitivity was notably low at 0.2105. The C-statistic for the LR method was 0.9018 and for the CNN method was 0.8830. Conclusions: Both the LR and CNN methods demonstrate good performance in identifying major bleeding in patients with postoperative malignant tumors from electronic medical records, exhibiting high sensitivity and specificity. Given the higher sensitivity of the LR method (89.47%) and the higher specificity of the CNN method (89.24%) in the test set, both models hold promise for practical application, depending on specific clinical priorities.

  • Open Access

    An Observational Study Evaluating the Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients Undergoing Surgery for Non‐Small Cell Lung Cancer

    by Xin Ye, Jinbai Miao, Hui Li, Bin Hu

    Objective: This study was conducted to investigate the safety of neoadjuvant immunotherapy combined with chemotherapy in patients undergoing surgery for resectable stage III non‐small cell lung cancer (NSCLC).Methods: Overall, 68 surgical patients with stage III NSCLC who underwent neoadjuvant therapy at the Thoracic Surgery Department of Beijing Chaoyang Hospital from June 2019 to September 2021 were included, including 19 patients who underwent neoadjuvant chemotherapy combined with immunotherapy and 49 who underwent neoadjuvant chemotherapy alone. Both groups of patients were diagnosed with NSCLC before treatment and had resectable stage III tumors. The surgical duration, blood loss volume, average postoperative hospital length of stay, intensive care unit length of stay, and complication rate were compared between the two groups.Results: The group treated with neoadjuvant chemotherapy combined with immunotherapy demonstrated higher values than the group treated with chemotherapy alone for surgical duration, blood loss volume, and rate of conversion to thoracotomy; however, the differences were not statistically significant. The incidence of postoperative complications in the group treated with neoadjuvant immunotherapy combined with chemotherapy was significantly higher than that of the group treated with neoadjuvant chemotherapy alone (p = 0.02).Conclusion: Neoadjuvant immunotherapy combined with chemotherapy was safe and effective and did not increase the difficulty of surgery for NSCLC; however, it was associated with a higher incidence of complications than neoadjuvant chemotherapy alone (p < 0.05).

  • Open Access

    Supplementary Fig. 3 from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    MSL3P1 regulates the invasion through CUL3 in LUAD.

  • Open Access

    Supplementary Fig.4 from Long Noncoding RNA MSL3P1 Regulates CUL3 mRNA Cytoplasmic Transport and Stability and Promotes Lung Adenocarcinoma Metastasis

    by Ming-Ming Shao, Xin Li, Rui-Qi Wei, Qing-Yu Chen, Xin Zhang, Xin Qiao, Hui Li

    Bioluminescence imaging of MSL3P1 knockdown or overexpression on the localization of LUAD cells in the lungs of nude mice.